Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 9, pp. 1925-1934
Open Access | Times Cited: 16

Showing 16 citing articles:

Sodium alginate-based drug delivery for diabetes management: A review
Mohammad Arshad Javed Shaikh, Gaurav Gupta, Obaid Afzal, et al.
International Journal of Biological Macromolecules (2023) Vol. 236, pp. 123986-123986
Closed Access | Times Cited: 34
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
Rosanna Maccari, Rosaria Ottanà
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 10848-10881
Open Access | Times Cited: 31
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 10, pp. 2207-2219
Open Access | Times Cited: 46
Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders
Arianna Maiorana, Francesco Tagliaferri, Carlo Dionisi‐Vici
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 15
Metabolic Approaches for the Treatment of Dilated Cardiomyopathy
Roberto Spoladore, Giuseppe Pinto, Francesca Daus, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 7, pp. 287-287
Open Access | Times Cited: 10
Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update
Ioanna Koniari, Dimitrios Velissaris, Nicholas G. Kounis, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 16, pp. 4660-4660
Open Access | Times Cited: 10
New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature
Antonia-Therese Kietaibl, Peter Fasching, Karl Glaser, et al.
Frontiers in Surgery (2022) Vol. 9
Open Access | Times Cited: 9
Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes
Alessio Bragagni, Federica Piani, Claudio Borghi
European Heart Journal Supplements (2021) Vol. 23, Iss. Supplement_E, pp. E40-E44
Open Access | Times Cited: 12
Exploring the mechanisms of action of gliflozines in heart failure and possible implications in pulmonary hypertension
Rosalinda Madonna
Vascular Pharmacology (2021) Vol. 138, pp. 106839-106839
Closed Access | Times Cited: 9
A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
Lianglan Shen, Hongli Yang, Xingxing Fang, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 1621-1630
Open Access | Times Cited: 6
Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial
G. P. Arutyunov, Yu. M. Lopatin, А С Аметов, et al.
Terapevticheskii arkhiv (2021) Vol. 93, Iss. 12, pp. 1491-1497
Open Access | Times Cited: 6
Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives
В. В. Салухов, G. R. Galstyan, T. A. Ilyinskay
Diabetes Mellitus (2022) Vol. 25, Iss. 3, pp. 275-287
Open Access | Times Cited: 4
Eligibility of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction: Insights from the Colombian heart failure registry (RECOLFACA)
Juan Esteban Gómez‐Mesa, Clara Saldarriaga, Alex Rivera-Toquica, et al.
IJC Heart & Vasculature (2024) Vol. 53, pp. 101448-101448
Open Access
Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial
Yu. M. Lopatin, G. P. Arutyunov, Ametov As, et al.
Russian Journal of Cardiology (2022) Vol. 27, Iss. 3, pp. 4945-4945
Open Access | Times Cited: 2
Update zur diastolisch bedingten Herzinsuffizienz
Caroline Morbach, Christoph Wanner, Stefan Störk
Deleted Journal (2022) Vol. 63, Iss. 7, pp. 798-804
Closed Access | Times Cited: 1
CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE
Мaryana М. Rоsul, Мyroslava М. Bletskan, Nataliya V. Ivano, et al.
Wiadomości Lekarskie (2023) Vol. 76, Iss. 3, pp. 645-650
Closed Access
Page 1

Scroll to top